ACT-A Dx Knowledge Hub

ACT-Accelerator Transition Plan (1 Oct 2022 to 31 Mar 2023)

This plan outlines how the ACT-Accelerator will support countries as the world transitions to long-term COVID-19 control.   

Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A’s set-up and ways of working, to ensure countries continue to have access to COVID-19 tools in the longer term, while maintaining the coalition’s readiness to help address future disease surges. 

Developed through a consultative process with ACT-A agencies, donors, industry partners, civil society organizations (CSOs) and Facilitation Council members, the plan summarizes priority areas of focus for the partnership’s pillars, coordination mechanisms and other core functions, and highlights the work to be maintained, transitioned, sunset, or kept on standby. 

The next phase of ACT-A partners’ work will centre on three overarching areas: 

  • Focusing research and development (R&D) and market shaping activities to ensure a pipeline for new and enhanced COVID-19 tools 
  • Securing institutional arrangements for sustained access for all countries to COVID-19 vaccines, tests and treatments, including oxygen 
  • Concentrating in-country work on new product introduction (e.g., new oral antivirals for those at highest risk) and protection of priority populations (e.g., full vaccination of health care workers and older populations), in support of national and international targets 

​Download Document

Related links:

Addendum to the ACT-Accelerator Transition Plan (1 Oct 2022 to 31 Mar 2023): Key learnings and perspectives from ACT-A Pillars and Partners to inform ongoing processes and discussions focused on strengthening the global health architecture for pandemic preparedness and response [NOTE: This document includes corrections implemented on 16 November 2022 to the sub-section on Therapeutics (pages iv – v).]

ACT-A Dx Knowledge Hub

© All Rights Reserved 2023

The ACT-A Dx Knowledge Hub is hosted by FIND on behalf of the ACT-Accelerator Diagnostics Pillar partnership.